REVIEW ON POTENTIAL IMPACTS OF HIGH-AFFINITY MODIFIED PROTEIN RBD-62 USAGE FOR COVID TREATMENT

This review includes the proper aspects of designing an antiviral drug, with the application of pharmacogenomics. The binding of SARS-CoV-2 involves attachment of itself onto the ACE2 human receptor, which primarily works on the conversion of ANG II (vasoconstrictor) to ANG 1-7 (vasodilation). This binding scenario leads to the release of the viral genome into the human cell for its own functioning and replication. Therefore, the binding of viral spike protein, receptor binding domain (RBD) of SARS-Cov2 can be prevented by administration of protein with no therapeutic functionality with enhanced adherence to ACE2 receptor, which could initiate a potential inhibitory mechanism against the viral genomic entry. This aim is achieved by the administration of RBD-62 laboratory made high-affinity variant of SARS-CoV2 spike protein, which can inhibit the attachment of SARS-CoV2 to the ACE2 receptor, therefore inhibit the viral genome entry.

Keywords: SARS-CoV2, ACE2, ANG II, ANG 1-7, RBD, spike protein, RBD-62.